Ryan D Assaf1, Marjan Javanbakht1, Elissa Meites2, Beau Gratzer3, Martin Steinau4, Richard A Crosby5, Lauri E Markowitz2, Elizabeth R Unger4, Pamina M Gorbach1. 1. From the Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA. 2. Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA. 3. Howard Brown Health, Chicago, IL. 4. Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA. 5. College of Public Health, University of Kentucky, Lexington, KY.
Abstract
BACKGROUND: Human papillomavirus (HPV) is a common sexually transmitted infection. Men who have sex with men (MSM) and transgender women (TGW) are at high risk for anal HPV infection and subsequent anal cancer. This study assessed the association of partner discordances with prevalent high-risk anal HPV (HRAHPV) among MSM and TGW. METHODS: Participants were enrolled in the cross-sectional young men's HPV study of gay, bisexual, and other MSM, and TGW, aged 18 to 26 years, from 2 cities. Participants completed a confidential standardized computer-assisted interview and provided self-collected anal swabs for type-specific HPV DNA testing. Multivariate analyses were conducted for 3 discordances of interest (i.e., partner age, race/ethnicity, and concurrent partner) to calculate adjusted odds ratios (aOR) and 95% confidence intervals (CI). RESULTS: Eight hundred sixty-two participants were included for partner race/ethnicity discordance, 601 for partner age discordance, and 581 for concurrent partner analysis. Most reported being older than 21 years, cisgender male, and gay. Adjusted odds of HRAHPV were not significantly increased among participants reporting partner age discrepancy >10 years (aOR, 0.89; 95% CI, 0.51-1.56), partner race/ethnicity discordance (aOR, 0.88; CI, 0.62-1.24), or partner with concurrent partners (aOR, 0.85; 95% CI, 0.50-1.42), compared with those who did not. CONCLUSIONS: This analysis did not identify any partner discordances associated with HRAHPV. Because HPV infection can persist for years, sexual mixing patterns with early partners might be more relevant than the most recent sex partner. Prevalence of HRAHPV was high and could be preventable by preexposure vaccination, as recommended for everyone through age 26 years including MSM and TGW.
BACKGROUND: Human papillomavirus (HPV) is a common sexually transmitted infection. Men who have sex with men (MSM) and transgender women (TGW) are at high risk for anal HPV infection and subsequent anal cancer. This study assessed the association of partner discordances with prevalent high-risk anal HPV (HRAHPV) among MSM and TGW. METHODS: Participants were enrolled in the cross-sectional young men's HPV study of gay, bisexual, and other MSM, and TGW, aged 18 to 26 years, from 2 cities. Participants completed a confidential standardized computer-assisted interview and provided self-collected anal swabs for type-specific HPV DNA testing. Multivariate analyses were conducted for 3 discordances of interest (i.e., partner age, race/ethnicity, and concurrent partner) to calculate adjusted odds ratios (aOR) and 95% confidence intervals (CI). RESULTS: Eight hundred sixty-two participants were included for partner race/ethnicity discordance, 601 for partner age discordance, and 581 for concurrent partner analysis. Most reported being older than 21 years, cisgender male, and gay. Adjusted odds of HRAHPV were not significantly increased among participants reporting partner age discrepancy >10 years (aOR, 0.89; 95% CI, 0.51-1.56), partner race/ethnicity discordance (aOR, 0.88; CI, 0.62-1.24), or partner with concurrent partners (aOR, 0.85; 95% CI, 0.50-1.42), compared with those who did not. CONCLUSIONS: This analysis did not identify any partner discordances associated with HRAHPV. Because HPV infection can persist for years, sexual mixing patterns with early partners might be more relevant than the most recent sex partner. Prevalence of HRAHPV was high and could be preventable by preexposure vaccination, as recommended for everyone through age 26 years including MSM and TGW.
Authors: Dorothy A Machalek; Mary Poynten; Fengyi Jin; Christopher K Fairley; Annabelle Farnsworth; Suzanne M Garland; Richard J Hillman; Kathy Petoumenos; Jennifer Roberts; Sepehr N Tabrizi; David J Templeton; Andrew E Grulich Journal: Lancet Oncol Date: 2012-03-23 Impact factor: 41.316
Authors: S O Aral; J P Hughes; B Stoner; W Whittington; H H Handsfield; R M Anderson; K K Holmes Journal: Am J Public Health Date: 1999-06 Impact factor: 9.308
Authors: Staci L Sudenga; Alan G Nyitray; B Nelson Torres; Roberto Silva; Luisa Villa; Eduardo Lazcano-Ponce; Martha Abrahamsen; Maria Luiza Baggio; Jorge Salmeron; Manuel Quiterio; Anna R Giuliano Journal: J Infect Date: 2017-03-28 Impact factor: 6.072
Authors: Pamina M Gorbach; Ryan Cook; Beau Gratzer; Thomas Collins; Adam Parrish; Janell Moore; Peter R Kerndt; Richard A Crosby; Lauri E Markowitz; Elissa Meites Journal: Sex Transm Dis Date: 2017-07 Impact factor: 2.830
Authors: Janet R Daling; Margaret M Madeleine; Lisa Godefroy Johnson; Stephen M Schwartz; Katherine A Shera; Michelle A Wurscher; Joseph J Carter; Peggy L Porter; Denise A Galloway; James K McDougall Journal: Cancer Date: 2004-07-15 Impact factor: 6.860
Authors: Djenaba A Joseph; Jacqueline W Miller; Xiaocheng Wu; Vivien W Chen; Cyllene R Morris; Marc T Goodman; Jose M Villalon-Gomez; Melanie A Williams; Rosemary D Cress Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: S A Raza; S Franceschi; S Pallardy; F R Malik; B I Avan; A Zafar; S H Ali; S Pervez; S Serajuddaula; P J F Snijders; F J van Kemenade; C J L M Meijer; S Shershah; G M Clifford Journal: Br J Cancer Date: 2010-04-20 Impact factor: 7.640
Authors: Elissa Meites; Pamina M Gorbach; Beau Gratzer; Gitika Panicker; Martin Steinau; Tom Collins; Adam Parrish; Cody Randel; Mark McGrath; Steven Carrasco; Janell Moore; Akbar Zaidi; Jim Braxton; Peter R Kerndt; Elizabeth R Unger; Richard A Crosby; Lauri E Markowitz Journal: J Infect Dis Date: 2016-06-13 Impact factor: 5.226
Authors: E M King; R Gilson; S Beddows; K Soldan; K Panwar; C Young; P Prah; M Jit; W J Edmunds; P Sonnenberg Journal: Br J Cancer Date: 2015-03-19 Impact factor: 7.640
Authors: Elizabeth A Van Dyne; S Jane Henley; Mona Saraiya; Cheryll C Thomas; Lauri E Markowitz; Vicki B Benard Journal: MMWR Morb Mortal Wkly Rep Date: 2018-08-24 Impact factor: 17.586